fingolimod hydrochloride has been researched along with Allergic Encephalomyelitis in 83 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (15.66) | 29.6817 |
| 2010's | 56 (67.47) | 24.3611 |
| 2020's | 14 (16.87) | 2.80 |
| Authors | Studies |
|---|---|
| Aliomrani, M; Dayani, L; Dinani, MS; Hashempour, H; Taheri, A; Varshosaz, J | 1 |
| Holman, SP; Kasheke, GDS; Robertson, GS | 1 |
| Cabañas-Cotillas, M; Calahorra, L; Camacho-Toledano, C; Castillo-Triviño, T; Clemente, D; Comabella, M; Costa-Frossard, L; García-Arocha, J; García-Domínguez, JM; Machín-Díaz, I; Midaglia, L; Ortega, MC; Otaegui, D; Villar, LM | 1 |
| Bigaud, M; Ekici, A; Enders, M; Kapitza, C; Kirchner, P; Kuerten, S; Weier, A; Wörl, J | 1 |
| Abbaspour-Ravasjani, S; Bani, F; Beyrampour-Basmenj, H; Ebrahimi-Kalan, A; Gao, H; Ghadiri, T; Khodakarimi, S; Rahbarghazi, R; Sadeghi, MR; Seidi, K; Sepasi, T; Talebi, M; Zarebkohan, A | 1 |
| Bellen, HJ; Chung, HL; Kanca, O; Lee, HK; Lu, S; Mok, JW; Park, YJ; Perrimon, N; Tattikota, SG; Ye, Q; Zuo, Z | 1 |
| Cheng, X; Huang, W; Huang, Y; Nie, G; Qiu, W; Shen, S; Wang, H; Wu, S; Zhang, J; Zhao, Y | 1 |
| Carrier, B; Carter, L; Cracchiolo, CJ; Delp, T; Evonuk, KS; Ferenčić, Ž; Johnson, GA; Mager, R; Martinez, E; Marušić, S; Mattie, J; Naiman, Z; Petrosino, T; Plaisted, W; Schofield, K; Sprague, E; Stewart, Z; Wang, S; Yusuf, I | 1 |
| Olivero, G; Pittaluga, A; Roggeri, A; Usai, C; Vanmierlo, T | 1 |
| Engelhardt, B; Enzmann, G; Homann, T; Huwiler, A; Kleuser, B; Stark, H; Stepanovska, B; Tietz, S; Zivkovic, A | 1 |
| Ben-Zwi, M; Halimi, M; Karussis, D; Kassis, I; Petrou, P | 1 |
| Afzali, AM; Aly, L; Bauer, IJ; Beltrán, E; Buchholz, VR; Busch, DH; Domínguez Moreno, H; Dornmair, K; Franzenburg, S; Garg, G; Gasperi, C; Gerdes, LA; Grassmann, S; Hemmer, B; Hiltensperger, M; Jarosch, S; Kant, R; Kawakami, N; Kenet, S; Knier, B; Korn, T; Kümpfel, T; Lepennetier, G; Misgeld, T; Muschaweckh, A; Öllinger, R; Rad, R; Schober, K; Sie, C; Tyystjärvi, S | 1 |
| Dang, PT; Hale, MW; Kocovski, P; Marinis, S; Orian, JM; Tabassum-Sheikh, N | 1 |
| Bae, D; Baek, J; Ha, N; Kim, T; Ko, SM; Lee, JY; Lim, HS; Park, J; Som Jeong, D; Son, WC; Suh, D | 1 |
| de Paula Faria, D; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Vállez García, D | 1 |
| Miller, A; Staun-Ram, E | 1 |
| Banik, NL; Dasgupta, S; Miller, LG; Purohit, S; Ray, SK; Wang, G; Young, JA | 1 |
| Bail, K; Bharti, R; Foerstner, KU; Kleinschnitz, C; Koeniger, T; Kuerten, S; Notz, Q; Rovituso, DM; Schampel, A; Scholz, CJ; Schropp, V; Wunsch, M | 1 |
| Bettelli, E; Buckner, JH; Duhen, R; Eken, A; Fry, M; Kita, M; Oukka, M; Singh, AK | 1 |
| Dang, PT; Hale, MW; Kocovski, P; Kyran, EL; Li, Z; Orian, JM; Robinson, C | 1 |
| Fukazawa, T; Kinoshita, M; Koda, T; Kumanogoh, A; Miyazaki, Y; Mochizuki, H; Nakatsuji, Y; Namba, A; Niino, M; Okuno, T; Shimizu, M; Sugimoto, T; Takata, K; Yamashita, K | 1 |
| Beckmann, N; Doelemeyer, A; Dubost, V; Jivkov, M; Schmid, C; Smith, PA; Theil, D; Zurbruegg, S | 1 |
| Campos, MM; da Costa, JC; Gomez, MV; Greggio, S; Silva, RBM; Venturin, GT | 1 |
| Cao, R; Guo, L; Hou, H; Li, B; Quan, M; Song, X; Sun, H; Sun, Y; Zhang, J | 1 |
| Adusumalli, P; Anderson, SM; Brown, ML; Desai, SN; Fogal, SE; Haxhinasto, SA; Lewis, ND; Lukas, SM; Modis, LK; Patnaude, LA; Ryan, KR; Slavin, AJ; Stefanopoulos, DE | 1 |
| Brieland, JK; Chen, YJ; Kim, JH; O'Neal, J; O'Neil, SP; Song, SK; Trinkaus, K; Tu, TW; Wang, X | 1 |
| Ahmad, I; Deshmukh, VA; Gage, FH; Green, CC; Kerman, B; Kim, HJ; Kondo, T; Lairson, LL; Lawson, BR; Lyssiotis, CA; Padmanabhan, K; Schultz, PG; Swoboda, JG; Tardif, V; Theofilopoulos, AN | 1 |
| Breit, SN; Brown, DA; Hart, PH; Hassanpour, M; Li, H; Mohammad, MG; Ruitenberg, MJ; Sawchenko, PE; Tsai, VW | 1 |
| Calabresi, PA; Gocke, AR; Grishkan, IV; Hall, O; Klein, SL; Ntranos, A; Robinson, DP; Schott, JT; Tosi, DM | 1 |
| Dev, KK; Sheridan, GK | 1 |
| Blankenbach, K; Engelhardt, B; Enzmann, G; Fallegger, D; Homann, T; Huwiler, A; Imeri, F; Kleuser, B; Meyer zu Heringdorf, D; Pfeilschifter, J; Schwalm, S; Stark, H; Zivkovic, A | 1 |
| Capitolo, E; Chaabane, L; Colombo, E; Di Dario, M; Farina, C; Martino, G; Newcombe, J | 1 |
| Lovett-Racke, AE; Racke, MK; Yang, Y | 1 |
| Shoenfeld, Y; Steinman, L | 1 |
| Harada, H; Hattori, K; Hirose, J; Kawato, Y; Koshika, T; Maeda, M; Morokata, T; Nagasaka, Y; Okada, Y; Saito, R; Yamamoto, R | 1 |
| Airas, L; Anthony, DC; Dickens, AM; Elo, P; Eskola, O; Haaparanta-Solin, M; Johansson, J; Jones, PA; Marjamäki, P; Rinne, J; Solin, O; Trigg, W | 1 |
| Chopp, M; Ding, X; Elias, SB; Li, Y; Lu, M; Shang, X; Zhang, J; Zhang, ZG | 1 |
| Anstadt, EJ; Clark, RB; Fujiwara, M; Khanna, KM | 1 |
| Blaho, VA; Engelbrecht, E; Galvani, S; Han, MH; Hla, T; Kono, M; Liu, C; Proia, RL; Steinman, L; Swendeman, SL | 1 |
| Amato, MP; Annunziato, F; Buonvicino, D; Caporale, R; Cavone, L; Chiarugi, A; Felici, R; Hakiki, B; Lapucci, A; Maggi, L; Muzzi, M; Peruzzi, B; Pratesi, S | 1 |
| Chiba, K; Fukunari, A; Kataoka, H; Maeda, Y; Seki, N; Sugahara, K; Takemoto, K; Utsumi, H | 1 |
| Dhindsa, JS; Gill, GS; Grobelny, DW; Samuvel, DJ; Saxena, N; Singh, AK; Singh, I | 1 |
| Cao, R; Guo, L; Hou, H; Liu, X; Miao, J; Song, X; Sun, Y | 1 |
| de Bruin, NM; Geisslinger, G; Häußler, A; Jordan, H; Parnham, MJ; Schiffmann, S; Schmidt, M; Schmitz, K; Tafferner, N; Tegeder, I | 1 |
| Engelhardt, B; Huwiler, A; Imeri, F; Lyck, R; Pfeilschifter, J; Schwalm, S; Stark, H; Zivkovic, A | 1 |
| Bartels, A; Barth, S; Greve, B; Herrmann, MM; Schumann, KM; Weissert, R | 1 |
| Garris, CS; Griffin, CW; Han, MH; Huang, Y; Moreno, MA; Tsai, HC | 1 |
| Hahn, JN; Kaushik, DK; Mishra, MK; Silva, C; Wang, J; Yong, VW | 1 |
| Gil, C; Martín-Álvarez, R; Martínez, A; Mengod, G; Palomo, V; Paúl-Fernández, N | 1 |
| Kulkarni, P; Medishetti, R; Saxena, U; Sriram, D; Yellanki, S; Yogeeswari, P | 1 |
| Bonanno, G; Bonfiglio, T; Di Cesare Mannelli, L; Di Prisco, S; Ghelardini, C; Grilli, M; Marchi, M; Merega, E; Milanese, M; Olivero, G; Padolecchia, C; Pittaluga, A | 1 |
| Ciric, B; Gran, B; Li, X; Ma, CG; Rostami, A; Zhang, GX; Zhang, Y | 1 |
| Antel, J; Blain, M; Borucki, DM; Chao, CC; de Lima, KA; Healy, L; Kenison, JE; Quintana, FJ; Rothhammer, V; Takenaka, MC; Tjon, E; Wilz, A | 1 |
| Balatoni, B; Baumruker, T; Bornancin, F; Foster, CA; Howard, LM; Kinnunen, A; Mechtcheriakova, D; Sobanov, J; Storch, MK; Wlachos, A | 1 |
| Antel, JP; Miron, VE; Schubart, A | 1 |
| Eaton, R; Gonzalez, MI; Marshall, I; Papadopoulos, D; Patel, R; Philpott, KL; Reynolds, R; Richardson, JC; Rundle, J; Stretton, J | 1 |
| Brinkmann, V | 1 |
| Castilló, J; Horga, A; Montalban, X | 1 |
| Fontoura, P; Garren, H | 1 |
| Chiba, K; Fukunari, A; Kataoka, H; Koyama, M; Seki, N; Shimano, K; Sugahara, K; Sugita, T | 1 |
| Chun, J; Noguchi, K | 1 |
| Choi, JW; Chun, J; Gardell, SE; Herr, DR; Kennedy, G; Lee, CW; Lu, M; Noguchi, K; Rivera, R; Teo, ST; Yung, YC | 1 |
| Bähr, M; Diem, R; Hein, K; Hillgruber, C; Kretzschmar, B; McRae, BL; Rau, CR; Sättler, MB | 1 |
| Al-Izki, S; Baker, D; Giovannoni, G; Jackson, SJ; Pryce, G | 1 |
| Fujita, T; Kohno, T; Tsuji, T; Yoshida, Y | 1 |
| Aktas, O; Boyko, A; Hartung, HP; Ingwersen, J; Kieseier, B; Kuery, P | 1 |
| Bernardi, G; Centonze, D; De Chiara, V; Furlan, R; Lo Giudice, T; Martino, G; Martorana, A; Motta, C; Musella, A; Rossi, S; Studer, V | 1 |
| Gillingwater, TH | 1 |
| Cahalan, SM; Cameron, MD; Gonzalez-Cabrera, PJ; Kago, T; Leaf, NB; Nguyen, N; Rosen, H; Sarkisyan, G | 1 |
| Adachi, K; Chiba, K | 1 |
| García-Merino, JA; Sánchez, AJ | 1 |
| Chiba, K; Yoshii, N | 1 |
| Tar, L; Vécsei, L | 1 |
| Amemiya, H; Fujino, M; Funeshima, N; Kimura, H; Kitazawa, Y; Li, XK; Suzuki, S | 1 |
| Baumann, DR; Cannet, C; Foster, CA; Hiestand, P; Rausch, M; Rudin, M | 1 |
| Chun, J; Hale, J; Lariosa-Willingham, K; Lin, FF; Mandala, S; Rao, TS; Tham, CS; Webb, M; Yu, N | 1 |
| Bendszus, M; Stoll, G | 1 |
| Chiba, K; Fukunari, A; Kataoka, H; Koyama, M; Shimano, K; Sugahara, K; Teshima, K | 1 |
| Miller, D | 1 |
| Baumruker, T; Billich, A; Brinkmann, V | 1 |
| Balatoni, B; Beerli, C; Billich, A; Foster, CA; Hiestand, PC; Howard, LM; Persohn, E; Reuschel, R; Schwartz, M; Schweitzer, A | 1 |
| Balatoni, B; Foster, CA; Hiestand, PC; Koziel, A; Lambrou, GN; Schönborn, V; Storch, MK; Swoboda, EM; Weissert, R | 1 |
| Albert, R; Baumruker, T; Brinkmann, V; Bruns, C; Cottens, S; Davis, MD; Foster, CA; Heise, CE; Hiestand, P; Hof, R; Lynch, KR; Prieschl, E; Zollinger, M | 1 |
12 review(s) available for fingolimod hydrochloride and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Effector and regulatory B cells in Multiple Sclerosis.
Topics: Alemtuzumab; Animals; B-Lymphocyte Subsets; B-Lymphocytes, Regulatory; Crotonates; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Rituximab; Toluidines | 2017 |
Is T-bet a potential therapeutic target in multiple sclerosis?
Topics: Animals; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Immunotherapy; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine; T-Box Domain Proteins; Th17 Cells | 2014 |
Central nervous system-directed effects of FTY720 (fingolimod).
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2008 |
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Topics: Animals; Astrocytes; Brain; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gap Junctions; Humans; Immune System; Inflammation; Lymph Nodes; Lysophospholipids; Multiple Sclerosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2009 |
Fingolimod for relapsing multiple sclerosis: an update.
Topics: Administration, Oral; Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Sphingosine | 2010 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
Roles for lysophospholipid S1P receptors in multiple sclerosis.
Topics: Animals; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Inflammation; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Phosphorylation; Propylene Glycols; Receptors, Lysophospholipid; Signal Transduction; Sphingosine | 2011 |
Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Topics: Animals; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Chronic Progressive; Propylene Glycols; Sphingosine | 2012 |
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Topics: Animals; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocytes; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Secondary Prevention; Sphingosine; Th17 Cells | 2012 |
[Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Cardiovascular System; Central Nervous System; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Lysophospholipids; Multiple Sclerosis; Organophosphates; Propylene Glycols; Sphingosine; Th17 Cells; Treatment Outcome | 2012 |
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Topics: Animals; Central Nervous System; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Endothelium, Lymphatic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2007 |
71 other study(ies) available for fingolimod hydrochloride and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Immunomodulatory effects of cyclotides isolated from Viola odorata in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis.
Topics: Amino Acid Sequence; Animals; Cyclotides; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Inflammation; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Viola; Water | 2022 |
Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gait; Mice; Mice, Inbred C57BL; Multiple Sclerosis, Relapsing-Remitting; Spinal Cord | 2022 |
Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.
Topics: Animals; Biomarkers; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Leukocytes, Mononuclear; Mice; Multiple Sclerosis; Myeloid-Derived Suppressor Cells | 2022 |
Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
Topics: Animals; Benzyl Compounds; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Mice; Multiple Sclerosis | 2022 |
CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice.
Topics: Animals; Chitosan; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Mice; Mice, Inbred C57BL; Nanoparticles; T-Lymphocytes | 2023 |
Very-long-chain fatty acids induce glial-derived sphingosine-1-phosphate synthesis, secretion, and neuroinflammation.
Topics: Animals; Bezafibrate; Encephalomyelitis, Autoimmune, Experimental; Fatty Acids; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Multiple Sclerosis; Neuroglia; Neuroinflammatory Diseases; Propylene Glycols | 2023 |
Targeting L-Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; L-Selectin; Lymph Nodes; Lymphocytes; Mice; Multiple Sclerosis; Pharmaceutical Preparations; Sphingosine | 2023 |
Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Mice; Mice, Biozzi; Myeloid Cells | 2023 |
Presynaptic Release-Regulating Sphingosine 1-Phosphate 1/3 Receptors in Cortical Glutamatergic Terminals: Adaptations in EAE Mice and Impact of Therapeutic FTY720.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glutamic Acid; Mice; Sphingosine-1-Phosphate Receptors | 2023 |
Morpholino Analogues of Fingolimod as Novel and Selective S1P
Topics: Animals; Central Nervous System; CHO Cells; Cricetulus; Disease Models, Animal; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Ligands; Lymphopenia; Lysophospholipids; Mice; Morpholinos; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Spinal Cord; T-Lymphocytes | 2020 |
Synergistic neuroprotective effects of Fingolimod and mesenchymal stem cells (MSC) in experimental autoimmune encephalomyelitis.
Topics: Animals; Apoptosis; Astrocytes; Biomarkers; Cell Differentiation; Cell Proliferation; Cytokines; Disease Management; Disease Models, Animal; Disease Susceptibility; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunomodulation; Immunophenotyping; Inflammation Mediators; Mesenchymal Stem Cells; Mice; Microglia; Neuroprotective Agents; Oxidative Stress | 2021 |
Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity.
Topics: Adoptive Transfer; Animals; Autoimmunity; Brain; Calcium Signaling; Cell Lineage; Cerebrospinal Fluid; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gene Expression Profiling; Genes, T-Cell Receptor; HEK293 Cells; Humans; Immunosuppressive Agents; Intestines; Intravital Microscopy; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Multiple Sclerosis, Relapsing-Remitting; Phenotype; Prospective Studies; Receptors, CXCR6; Receptors, Purinergic P2X7; RNA-Seq; Single-Cell Analysis; Skin; T-Lymphocytes, Helper-Inducer; Transcriptome | 2021 |
Immunomodulation Eliminates Inflammation in the Hippocampus in Experimental Autoimmune Encephalomyelitis, but Does Not Ameliorate Anxiety-Like Behavior.
Topics: Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Down-Regulation; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hippocampus; Immunomodulation; Inflammation; Mice; Mice, Inbred C57BL; Microglia; Signal Transduction; Sphingosine-1-Phosphate Receptors; Up-Regulation | 2021 |
CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis.
Topics: Animals; Antidepressive Agents; Blood-Brain Barrier; Cell Proliferation; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Macrophages; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Spinal Cord; T-Lymphocytes | 2021 |
Effect of Preventive and Curative Fingolimod Treatment Regimens on Microglia Activation and Disease Progression in a Rat Model of Multiple Sclerosis.
Topics: Animals; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Microglia; Multiple Sclerosis; Rats | 2017 |
Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation.
Topics: Animals; Ceramides; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Rats; Serine C-Palmitoyltransferase; Sphingosine; Spinal Cord | 2017 |
Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.
Topics: Animals; Antigens, CD19; B-Lymphocytes; Calcium-Binding Proteins; CD4-Positive T-Lymphocytes; Cell Aggregation; Central Nervous System; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunospot Assay; Female; Fingolimod Hydrochloride; Flow Cytometry; Freund's Adjuvant; Immunosuppressive Agents; Lymph Nodes; Mice; Myelin Basic Protein; Myelin Proteolipid Protein; Recombinant Fusion Proteins; Spleen; Time Factors | 2017 |
S1P
Topics: Animals; Autoimmunity; Case-Control Studies; Disease Susceptibility; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gene Deletion; Humans; Inflammation; Lymphadenopathy; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Organ Specificity; Phenotype; Receptors, Lysosphingolipid; T-Lymphocytes, Regulatory; Th17 Cells; Transcription, Genetic | 2017 |
Multiple pathological mechanisms contribute to hippocampal damage in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Topics: alpha-Crystallin B Chain; Animals; CD3 Complex; Choroid Plexus; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hippocampus; Immunohistochemistry; Immunosuppressive Agents; Lateral Ventricles; Lymphocytes; Meninges; Mice, Inbred C57BL; Microglia | 2018 |
Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
Topics: Adult; Animals; Antirheumatic Agents; Biomarkers; Disease Progression; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Drug Substitution; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Interferon-beta; Lymphocyte Count; Male; Mice; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recombinant Fusion Proteins; Retrospective Studies; Semaphorins; Severity of Illness Index; Specific Pathogen-Free Organisms; Treatment Outcome | 2018 |
Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
Topics: Animals; Atrophy; Brain; Brain-Derived Neurotrophic Factor; Crotonates; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hydroxybutyrates; Immunosuppressive Agents; Interleukin-17; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Nitriles; Toluidines | 2018 |
Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Calcium Channel Blockers; Chemokines; Cognition Disorders; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hyperalgesia; Inflammation; Inflammation Mediators; Injections, Spinal; Mice, Inbred C57BL; Motor Activity; Multiple Sclerosis; Myelin Sheath; Myelin-Oligodendrocyte Glycoprotein; Nociception; omega-Conotoxins; Peptide Fragments | 2018 |
Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.
Topics: Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-akt; Sirolimus; T-Lymphocytes, Regulatory; Th17 Cells; TOR Serine-Threonine Kinases | 2018 |
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Topics: Animals; Bone Marrow; Cell Movement; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Killer Cells, Natural; Leukocyte Count; Mice; Monocytes; Neutrophils; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; Spleen | 2013 |
Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice.
Topics: Animals; Anisotropy; Diffusion Tensor Imaging; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Mice; Mice, Inbred C57BL; Myelin Basic Protein; Propylene Glycols; Sphingosine; Spine | 2013 |
A regenerative approach to the treatment of multiple sclerosis.
Topics: Animals; Antiparkinson Agents; Benztropine; Cell Differentiation; Coculture Techniques; Cuprizone; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immune System; Mice; Mice, Inbred C57BL; Models, Biological; Multiple Sclerosis; Myelin Proteolipid Protein; Myelin Sheath; Oligodendroglia; Optic Nerve; Propylene Glycols; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M3; Recurrence; Regeneration; Sphingosine; Stem Cells | 2013 |
Immune cell trafficking from the brain maintains CNS immune tolerance.
Topics: Animals; CD11 Antigens; Cell Movement; Cells, Cultured; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immune Tolerance; Lymph Nodes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neck; Propylene Glycols; Prosencephalon; Sphingosine; T-Lymphocytes, Regulatory | 2014 |
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Topics: Animals; CD8-Positive T-Lymphocytes; Chemotaxis, Leukocyte; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Flow Cytometry; Granzymes; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Interferon-gamma; Lysophospholipids; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Propylene Glycols; Signal Transduction; Sphingosine | 2014 |
Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.
Topics: Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, Inbred C57BL; Motor Activity; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Vocalization, Animal | 2014 |
Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Topics: Animals; Cell Line; Cell Membrane Permeability; Cells, Cultured; Chemotaxis; CHO Cells; Cricetulus; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Mice; Mice, Inbred C57BL; Oxazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes; U937 Cells | 2014 |
Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Topics: Aged; Animals; Astrocytes; Cells, Cultured; Cerebrum; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis; Neuroprotective Agents; Nitric Oxide; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-1 Type I; Receptors, Interleukin-17; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Spinal Cord | 2014 |
From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela.
Topics: Animals; Antibodies, Monoclonal, Humanized; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glatiramer Acetate; History, 20th Century; History, 21st Century; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Peptides; Propylene Glycols; Sphingosine | 2014 |
ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
Topics: Animals; Benzimidazoles; Blood Pressure; Bronchoconstriction; Cell Line; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Heart Rate; Lymphocytes; Male; Mice; Oxadiazoles; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2014 |
In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.
Topics: Animals; Autoradiography; BCG Vaccine; Carrier Proteins; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Freund's Adjuvant; Immunohistochemistry; Immunosuppressive Agents; Inflammation; Ligands; Male; Microglia; Multiple Sclerosis; Positron-Emission Tomography; Propylene Glycols; Rats; Rats, Inbred Lew; Receptors, GABA-A; Sphingosine; Time Factors | 2015 |
Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis.
Topics: Animals; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hedgehog Proteins; Mice; Myelin Sheath; Oligodendroglia; Severity of Illness Index; Signal Transduction; Stem Cells | 2015 |
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Topics: Adaptor Proteins, Signal Transducing; Adoptive Transfer; Animals; Cell Movement; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Homeodomain Proteins; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Knockout; Multiple Sclerosis; Propylene Glycols; Proto-Oncogene Proteins c-cbl; Sphingosine; T-Lymphocytes | 2015 |
HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation.
Topics: Animals; Apolipoproteins; Apolipoproteins M; Blood-Brain Barrier; Cell Movement; Cell Proliferation; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cells; Inflammation; Lipoproteins, HDL; Lymphocytes; Lymphoid Progenitor Cells; Lymphopoiesis; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2015 |
Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Receptors, Lysosphingolipid; Signal Transduction; Spinal Cord; T-Lymphocytes, Regulatory | 2015 |
IL-17-Producing Vγ4+ γδ T Cells Require Sphingosine 1-Phosphate Receptor 1 for Their Egress from the Lymph Nodes under Homeostatic and Inflammatory Conditions.
Topics: Animals; Cell Movement; Dermatitis; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Homeostasis; Immunosuppressive Agents; Inflammation; Interleukin-17; Lymph Nodes; Male; Mice; Proprotein Convertases; Receptors, Antigen, T-Cell, gamma-delta; Receptors, Lysosphingolipid; Serine Endopeptidases; T-Lymphocyte Subsets; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2015 |
AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
Topics: Animals; Capillary Permeability; Cell Membrane; CHO Cells; Cricetulus; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Extracellular Signal-Regulated MAP Kinases; Female; Fingolimod Hydrochloride; Heart Rate; Lymphocyte Count; Multiple Sclerosis; Proteolysis; Proto-Oncogene Proteins c-akt; Rats; Receptors, Lysosphingolipid; T-Lymphocyte Subsets | 2015 |
Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Oncogene Protein v-akt; Receptors, Lysosphingolipid; Signal Transduction; TOR Serine-Threonine Kinases; United States; United States Food and Drug Administration | 2016 |
Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis.
Topics: Animals; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gait; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Motor Activity; Rats, Inbred Lew; Recognition, Psychology; Severity of Illness Index; Social Behavior; Time | 2016 |
Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments.
Topics: Animals; Blood-Brain Barrier; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Fingolimod Hydrochloride; Gene Knockdown Techniques; Immunologic Factors; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred C57BL; Oxazoles; Phosphotransferases (Alcohol Group Acceptor); Primary Cell Culture; RNA, Messenger; T-Lymphocytes | 2016 |
Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis.
Topics: ADP-ribosyl Cyclase 1; Animals; Cell Movement; Chemokine CXCL12; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Profiling; Gene Expression Regulation; Humans; Immunization; Lymph Nodes; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Peptides; Rats; Receptors, CXCR4; RNA, Messenger; Spinal Cord | 2016 |
Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Phosphorylation; Receptors, CCR6; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors | 2016 |
Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.
Topics: Animals; Anti-Bacterial Agents; Basigin; Central Nervous System; Clinical Trials, Phase III as Topic; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Interferon-beta; Lymphocyte Activation; Maleates; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Minocycline; Monocytes; Multiple Sclerosis; T-Lymphocytes; Tissue Inhibitor of Metalloproteinase-1 | 2016 |
A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice.
Topics: Animals; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 7; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Lymphocytes; Mice; Mice, Inbred C57BL; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Phosphodiesterase Inhibitors; Spinal Cord; Tumor Necrosis Factor-alpha | 2017 |
Novel Zebrafish EAE model: A quick in vivo screen for multiple sclerosis.
Topics: Animals; Dexamethasone; Dimethyl Fumarate; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunologic Factors; Phenotype; Sulfonamides; Thiazoles; Video Recording; Zebrafish | 2017 |
Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis.
Topics: Administration, Oral; Animals; Cerebral Cortex; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Exocytosis; Female; Fingolimod Hydrochloride; gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Neuroglia; Organ Specificity; Spinal Cord; Synapses | 2017 |
Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Humans; Mice; Multiple Sclerosis; Myelin Sheath; Nerve Regeneration; Neural Stem Cells; Oligodendroglia; Receptors, Lysosphingolipid; Signal Transduction; Stem Cell Transplantation; Treatment Outcome | 2017 |
Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
Topics: Animals; Astrocytes; Cell Line, Tumor; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Microglia; Monocytes; Multiple Sclerosis, Chronic Progressive; Primary Cell Culture; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Transcriptome | 2017 |
FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.
Topics: Animals; Antigens; Blood-Brain Barrier; Blotting, Western; Brain; Capillary Permeability; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunization; Immunosuppressive Agents; Myelin Proteins; Phospholipases A2, Cytosolic; Polymerase Chain Reaction; Propylene Glycols; Random Allocation; Rats; Sphingosine; Spinal Cord | 2009 |
FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
Topics: Animals; Autoantibodies; Axons; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Propylene Glycols; Rats; Rats, Inbred Strains; Recombinant Proteins; Severity of Illness Index; Sphingosine; Spinal Cord; Time Factors | 2010 |
Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
Topics: Animals; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Mice; Mice, Inbred C57BL; Myelin Proteolipid Protein; Propylene Glycols; Sphingosine | 2011 |
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Topics: Animals; Astrocytes; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Multiple Sclerosis; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2011 |
Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Disease Models, Animal; Electrophysiology; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Glycoproteins; Immunosuppressive Agents; Myelin Sheath; Neurons; Oligodendroglia; Optic Neuritis; Propylene Glycols; Rats; Sphingosine | 2011 |
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.
Topics: Animals; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Mice; Nerve Degeneration; Propylene Glycols; Recovery of Function; Sphingosine | 2011 |
Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
Topics: Animals; Autoantigens; Cyclosporine; Demyelinating Diseases; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Glycoproteins; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Nerve Tissue Proteins; Peptide Fragments; Propylene Glycols; Remission Induction; Secondary Prevention; Specific Pathogen-Free Organisms; Sphingosine; Spinal Cord | 2011 |
Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
Topics: Animals; Dendritic Spines; Encephalomyelitis, Autoimmune, Experimental; Excitatory Postsynaptic Potentials; Female; Fingolimod Hydrochloride; Glutamic Acid; Glycoproteins; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Propylene Glycols; Sphingosine; Synapses; Synaptic Transmission | 2012 |
Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Multiple Sclerosis; Propylene Glycols; Sphingosine; Synapses | 2012 |
S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
Topics: Animals; Central Nervous System; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Indans; Lymphopenia; Mice; Multiple Sclerosis; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
[Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
Topics: Animals; Atrophy; B-Lymphocytes; Brain; Cell Movement; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; L-Selectin; Lysophospholipids; Mice; Molecular Structure; Multiple Sclerosis; Neuroglia; Propylene Glycols; Rats; Receptors, CCR7; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocyte Subsets; Th17 Cells | 2012 |
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
Topics: Animals; Apoptosis; Central Nervous System; Central Nervous System Diseases; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; T-Lymphocytes | 2003 |
Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Topics: Acute Disease; Animals; Blood-Brain Barrier; Brain; Contrast Media; Dextrans; Encephalomyelitis, Autoimmune, Experimental; Female; Ferrosoferric Oxide; Fingolimod Hydrochloride; Heterocyclic Compounds; Immunohistochemistry; Immunosuppressive Agents; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organometallic Compounds; Oxides; Propylene Glycols; Rats; Rats, Inbred Lew; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recurrence; Sphingosine | 2004 |
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Immunosuppressive Agents; Interferon-gamma; Lymphocytes; Lymphopenia; Mice; Mice, Inbred Strains; Mitoxantrone; Molecular Sequence Data; Myelin Proteins; Myelin Proteolipid Protein; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peptide Fragments; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sphingosine; Time Factors | 2004 |
Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in experimental autoimmune encephalitis.
Topics: Animals; Blood-Brain Barrier; Brain; Contrast Media; Dextrans; Encephalomyelitis, Autoimmune, Experimental; Ferrosoferric Oxide; Fingolimod Hydrochloride; Heterocyclic Compounds; Immunohistochemistry; Immunosuppressive Agents; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Organometallic Compounds; Oxides; Propylene Glycols; Rats; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recurrence; Sphingosine | 2005 |
FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glycoproteins; Male; Mice; Myelin Basic Protein; Myelin Proteolipid Protein; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2005 |
Multiple sclerosis: new insights and therapeutic progress.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain; Canada; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interleukin-18; Multiple Sclerosis; Natalizumab; Propylene Glycols; Randomized Controlled Trials as Topic; Sex Factors; Sphingosine | 2007 |
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Topics: Administration, Oral; Animals; Autoradiography; Brain; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocyte Count; Multiple Sclerosis; Phosphorylation; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine | 2007 |
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.
Topics: Analysis of Variance; Animals; Body Weight; Disease Models, Animal; Electric Stimulation; Encephalomyelitis, Autoimmune, Experimental; Evoked Potentials, Somatosensory; Evoked Potentials, Visual; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Longitudinal Studies; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Neural Conduction; Propylene Glycols; Rats; Reaction Time; Sphingosine; Spinal Cord; Time Factors | 2007 |
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Topics: Animals; Apoptosis; Cell Line; Cell Membrane; Chemotaxis; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Insecta; Kidney; Lipid Metabolism; Lymphocytes; Lymphopenia; Mice; Models, Chemical; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Rats; Rats, Inbred Lew; Rats, Wistar; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Recombinant Proteins; Signal Transduction; Sphingosine; Time Factors | 2002 |